Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: Effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations
A Honda, S Shefer, G Salen, G Xu, A K Batta, G S Tint, M Honda, T C Chen, M F Holick – 1 August 1996 – The Smith‐Lemli‐Opitz syndrome is a common inherited birth disorder caused by markedly reduced 7‐dehydrocholesterol δ7‐reductase activity, the final enzyme in the cholesterol biosynthetic pathway. BM 15.766 (4‐[2‐[1‐(4‐chlorocinnamyl)piperazin‐4‐yl]ethyl]‐benzoic acid) inhibits 7‐dehydrocholesterol delta 7‐reductase activity, reduces plasma cholesterol levels, and increases 7‐dehydrocholesterol levels to reproduce the biochemical abnormalities of the syndrome in rats.